Table 2.
Classification of patients with the outcome of late treatment failure, DRC therapeutic efficacy study, 2017
| Kabondo | Kapolowe | Kimpese | Mikalayi | Rutshuru | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AL (N = 83) | ASAQ (N = 81) | DP (N = 74) | AL (N = 93) | ASAQ (N = 89) | DP (N = 92) | AL (N = 74) | ASAQ (N = 82) | DP (N = 81) | AL (N = 92) | ASAQ (N = 84) | DP (N = 88) | AL (N = 89) | ASAQ (N = 82) | DP (N = 87) | |
| Early treatment failure | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Late treatment failure | 10 | 0 | 7 | 23 | 0 | 33 | 11 | 6 | 8 | 34 | 20 | 39 | 18 | 23 | 36 |
| Recrudescence* | 1 | 0 | 0 | 4 | 0 | 6 | 2 | 0 | 0 | 14 | 3 | 12 | 3 | 6 | 3 |
| Day 7–13 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Day 14–21 | 1 | 0 | 0 | 1 | 0 | 1 | 1 | 0 | 0 | 3 | 2 | 1 | 2 | 1 | 1 |
| Day 22–28 | 0 | 0 | 0 | 3 | 0 | 1 | 1 | 0 | 0 | 11 | 1 | 1 | 1 | 5 | 1 |
| Day 29–35 | – | – | 0 | – | – | 2 | – | – | 0 | – | – | 6 | – | – | 1 |
| Day 36–42 | – | – | 0 | – | – | 2 | – | – | 0 | – | – | 4 | – | – | 0 |
| Reinfection | 9 | 0 | 7 | 19 | 0 | 27 | 9 | 6 | 8 | 20 | 17 | 27 | 15 | 17 | 34 |
| Day 7–13 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Day 14–21 | 1 | 0 | 1 | 10 | 0 | 1 | 7 | 1 | 1 | 7 | 8 | 3 | 4 | 12 | 9 |
| Day 22–28 | 8 | 0 | 0 | 9 | 0 | 7 | 2 | 4 | 7 | 13 | 9 | 10 | 11 | 5 | 11 |
| Day 29–35 | – | – | 4 | – | – | 11 | – | – | 0 | – | – | 8 | – | – | 9 |
| Day 36–42 | – | – | 2 | – | – | 8 | – | – | 0 | – | – | 6 | – | – | 5 |
| ACPR | 73 | 81 | 67 | 70 | 89 | 59 | 63 | 74 | 73 | 58 | 64 | 49 | 71 | 59 | 51 |
ACPR = adequate clinical and parasitological response; AL = artemether-lumefantrine; ASAQ = artesunate-amodiaquine; DP = dihydroartemisinin-piperaquine; DRC = Democratic Republic of the Congo.
*
Recrudescence defined as a late failure with a posterior probability of recrudescence ≥ 0.5.